Evidence map›Paper›PMID 40086910›Full record

Trial reportInternational psychogeriatrics2025

Correlation between changes in apathy and cognition in Alzheimer's disease associated apathy: Analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).

Krushnaa Sankhe, Shankar Tumati, Jamie Perin, Luc Rivet, Danielle Vieira, Paul B Rosenberg, Nathan Herrmann, David Shade, Alan J Lerner, Prasad R Padala and 7 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International psychogeriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Krushnaa SankheSunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
Shankar TumatiSunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
Jamie PerinJohns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA.
Luc RivetSunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
Danielle VieiraSunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
Paul B RosenbergJohns Hopkins University, Department of Medicine, Baltimore, MD, USA.
Nathan HerrmannSunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
David ShadeJohns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA.
Alan J LernerUniversity Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Prasad R PadalaCentral Arkansas Veterans Healthcare System, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Olga Brawman-MintzerRalph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC, USA.
Christopher H van DyckYale School of Medicine, New Haven, CT, USA.
Anton P PorsteinssonUniversity of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Suzanne CraftWake Forest University, Winston-Salem, NC, USA.
Allan I LeveyEmory Goizueta Alzheimer's Disease Research Center, Atlanta, GA, USA.
Jacobo MintzerRalph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC, USA.
Krista L LanctôtSunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada. Electronic address: krista.lanctot@sunnybrook.ca.

Funding

Wake Forest University School of Medicine Alzheimer's Disease Research CenterP30AG072947 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SUZANNE CRAFT · 2021 to 2026
$24.3M
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)R01AG046543 · NIA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HERRMANN, NATHAN, LANCTOT, KRISTA L. · 2014 to 2018
$8.1M
NIA NIH HHS P30 AG072947NIA NIH HHS R01 AG046543
6 · The paper itself

Abstract

backgroundPrevious trials have shown improvements in both apathy and cognition with methylphenidate (MPH).

objectivesTo assess whether changes in apathy correlated with changes in cognition in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).

participantsMild to moderate AD patients with clinically significant apathy randomized to MPH (20 mg/day) or placebo for 6 months. MEASUREMENTS: Apathy was measured with the Neuropsychiatric Inventory-apathy (NPI-A) domain. Cognition was measured using the Mini-Mental State Exam (MMSE), Hopkins Verbal Learning (immediate [HVLT-I], delayed [HVLT-D] recall), Digit Span (Forward [DF], Backward [DB]), Trail Making (TMT-A, TMT-B), Action Verbal Fluency (AV), Category Fluency (CF), and the Short Boston Naming Test (BNT).

designLinear mixed models included cognitive change scores as dependent variables and time, treatment, change in NPI-A and the interaction between treatment and change in NPI-A as independent variables, which were additionally adjusted for baseline NPI-A and cognitive scores, age, sex, level of education and presence of diabetes.

results199 participants (66 % male) were included (98-MPH, 101-placebo). Among all participants, worsening CF was associated with worsening apathy (-0.15 (0.05), p = .003). In addition, change in HVLT-I was associated with the interaction between changes in apathy and treatment (-0.31 (0.07), p = 0.0000158).

conclusionChanges in apathy are mostly independent of cognitive changes and apathy response to MPH may be independent from cognition. These results are consistent with the view that apathy as a syndrome is related to but distinct from cognition.

Indexed as

Alzheimer DiseaseApathyCentral Nervous System StimulantsCognitionMethylphenidateAgedAged, 80 and overDouble-Blind MethodFemaleHumansMaleMental Status and Dementia TestsNeuropsychological TestsTreatment OutcomeCentral Nervous System StimulantsMethylphenidateAlzheimer’s diseaseApathyCognitionMethylphenidate

Identifiers

PMID40086910
PMCPMC12706841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.